The dominance of the US, and its technology companies in particular, has become an accepted feature of global stock markets.

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

BBI Solutions Limited ("BBI"), global leader in the development and manufacture of IVD reagents, announces a CEO succession. After 7 years as ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Globally, Novo Nordisk holds 65% of the market for GLP ... The company's ability to produce the next generation of weight loss medicines building on the success of Wegovy is now deeply in question.

Novo Nordisk is laying out 8.5 billion Danish kroner ... which has often focused on building out capacity for the company’s GLP-1 injectables for diabetes and obesity. Back in June, the company ...